News

This transaction marks another significant advancement in the group's strategic layout in the Latin American market, further consolidating its leading position in the global packaging industry.

BlockBeats News, March 3rd, Lido officially stated that the ZKsync wstETH bridge endpoint contract has a potential vulnerability. There is currently no evidence to suggest that the vulnerability has been exploited, and wstETH holders on ZKsync are unaffected. Other bridge contracts are unaffected. As a precautionary measure, Lido has temporarily paused new fund deposits to the ZKsync bridge contract, withdrawals from zkSync, and token transfers are unaffected. Lido has a fix prepared, which will be audited and deployed during the next scheduled on-chain Lido governance supermajority vote (late March/early April), after which the deposit functionality will resume. Further updates will be provided as the situation develops.

The institution has set a target stock price of $36 for the company, demonstrating a positive outlook on its future growth potential. This coverage marks an increased market focus on AgomAb Therapeutics' R&D pipeline. Leerink Partners' optimistic rating is based on an in-depth assessment of the company's core technology and business prospects.